Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O95319
UPID:
CELF2_HUMAN
Alternative names:
Bruno-like protein 3; CUG triplet repeat RNA-binding protein 2; CUG-BP- and ETR-3-like factor 2; ELAV-type RNA-binding protein 3; Neuroblastoma apoptosis-related RNA-binding protein; RNA-binding protein BRUNOL-3
Alternative UPACC:
O95319; B7ZAN9; Q7KYU4; Q8N499; Q92950; Q96NW9; Q96RQ5; Q96RQ6; Q9UL67
Background:
CUGBP Elav-like family member 2, known by alternative names such as Bruno-like protein 3 and Neuroblastoma apoptosis-related RNA-binding protein, plays a pivotal role in post-transcriptional gene regulation. It is involved in mRNA splicing, stability, and translation, affecting various cellular processes including muscle development and apoptosis.
Therapeutic significance:
Linked to Developmental and epileptic encephalopathy 97, a condition characterized by severe seizures and cognitive impairment, understanding the role of CUGBP Elav-like family member 2 could open doors to potential therapeutic strategies.